secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007858
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharmaceuticals adopts Executive Incentive Plan; sets 2023 salaries and 2022 bonuses for executives
--------------------------------------------------------------------------------

- CEO Ian Mortimer: 2022 non-equity bonus $343,422; 2023 base salary $665,000.
- CFO Sherry Aulin: 2022 bonus $178,619; 2023 base salary $465,000.
- CMO Christopher Kenney: 2022 bonus $195,300; 2023 base salary $510,000.
- CEO eligible for up to 60% base salary under new plan; CFO and CMO eligible for up to 40%.
- Incentive Compensation Plan allows cash awards based on corporate goals (R&D, regulatory, financial milestones).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/0000950170-23-007858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023007858/xene-20230310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer